Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2655${count})

  • Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2026
    Oxylipin Profiles in LRRK2 Mutation Carriers: Biomarkers for Parkinson’s Disease

    Study Rationale:                   

    Parkinson’s disease (PD) involves complex interactions between genetic factors, such as LRRK2 mutations, and lipid metabolism. Oxylipins, bioactive lipid mediators...

  • Research Grant, 2026
    Including a Watch to the Gait Substudy

    Aims and Hypothesis:

    Here we propose to leverage the gait sub-study and add a watch to a subset of participants who are anticipated to return for their second gait assessment. Such addition will enable...

  • Parkinson’s Disease Therapeutics Pipeline Program -Pre-Clinical, 2026
    CSM-101 TRPML1 Agonist for Parkinson’s Disease

    Study Rationale:                   

    The appropriate regulation of proteins and lipids within neurons is critical for human health. Lysosomes are specialized structures within cells that are responsible...

  • Research Grant, 2026
    Expansion of the NEULARK Study, Examining the Effects of NEU-411 on LRRK2-driven Parkinson’s Patients, Into Israel

    Study Rationale:                   

    LRRK2 is a gene that plays a role in the development and progression of Parkinson's disease (PD). Mutations in the LRRK2 gene can increase the risk of developing PD...

  • Research Grant, 2026
    Differential Expression of Aging-related Genes and Co-expression with SNCA and MAPT in Parkinson’s Disease Patients and Healthy Controls

    Study Rationale:                   

    Aging is the strongest risk factor for Parkinson’s disease, yet the biological reasons behind this connection remain unclear. Our recent findings suggest that...

  • Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biomarkers, 2026
    Metabolomic Biomarkers of PD Progression

    Study Rationale:                   

    We have identified small molecules associated with altered odds of having Parkinson's disease (PD) among hundreds of metabolites measured in metabolomic analyses of...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.